Abstract
Molecular profiling of tumor tissue is the gold standard for treatment decision making in advanced non-small cell lung cancer (NSCLC). However, tumor genotyping may be unavailable due to insufficient tissue samples. Plasma-based next-generation sequencing (NGS) is emerging as either complementary or alternative to standard tissue genotyping in advanced NSCLC. We present our experience using plasma-based NGS in advanced NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
